Focus issue: From genomic mutations to oncogenic pathways

This two-issue series focuses on how understanding how signaling pathways are altered in cancer cells can enable researchers to develop more effective therapies. Cancer is a pleiotropic disease. Tumor cells change over time and, even within a specific tumor, cells may have different mutations and dependencies on different signaling pathways for survival or for metastatic potential. New tools and technologies for genomic- or systems-level analysis, as well as conventional biochemistry and cell biology approaches, are revealing how signaling pathways contribute to cancer development, cancer evolution, and drug resistance.